Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSkye Bioscience, Inc. Common Stock

Skye Bioscience, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.919 USD 0.08 ( 9.54%)
Last update at 2026-11-11T21:00:00Z
VOLUME
83670
Market Cap
9.34M

Momentum Score

…

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.84
Low
0.92
High
52 Week Price Range
0.26
Low
4.99
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Skye Bioscience, Inc. is a small, publicly traded biotechnology company for which broadly available details about its product pipeline and commercial operations are limited. As an early-stage developer, long-term growth drivers would typically include clinical-trial progress and outcomes, regulatory approvals, licensing or collaboration agreements, and successful commercialization, any of which could support value creation for investors seeking exposure to novel therapeutics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.84
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-233.87%
Net Debt
-5.61M
ROCE
-278.09%
Diluted EPS TTM
-10.97

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -55.92M -26.56M -37.64M -19.47M -8.52M
Net income -55.92M -26.57M -37.64M -19.48M -8.52M
Selling general administrative 15.80M 17.73M 7.85M 6.09M 4.92M
Selling and marketing expenses - - 0.12M - -
Gross profit -0.72M -0.30M -0.12M - -
Reconciled depreciation 0.72M 0.30M 0.12M 0.11M 0.03M
Ebit -55.92M -25.59M -36.74M - -7.85M
Ebitda -55.20M -25.29M -36.62M -18.69M -7.72M
Depreciation and amortization 0.72M 0.30M 0.12M - -
Operating income -58.16M -30.19M -34.74M -12.11M -7.85M
Other operating expenses 58.16M 30.19M 34.74M - -
Interest expense 0.00M 0.97M 0.91M 0.67M 0.77M
Tax provision 0.01M 0.01M 0.00M 0.01M 0.00M
Interest income 1.88M 3.26M 0.10M 0.02M 0.00M
Net interest income 1.88M 2.28M -0.81M -0.77M -0.77M
Income tax expense 0.01M 0.01M 0.00M - 0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 57.44M 30.19M 34.74M 12.11M 7.85M
Cost of revenue 0.72M 0.30M 0.12M - -
Total other income expense net 2.24M 3.64M -2.91M -6.60M 0.10M
Net income from continuing ops -55.92M -26.57M -37.64M -19.48M -8.52M
Net income applicable to common shares - - - - -8.52M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 28.31M 72.76M 11.94M 9.11M 9.86M
Other current assets 1.35M 2.41M 10.24M 0.41M 0.06M
Total liab 8.29M 4.61M 14.07M 12.12M 3.99M
Total stockholder equity 20.02M 68.15M -2.13M -3.01M 5.86M
Other current liab 5.98M 3.59M 8.50M 7.57M 0.06M
Common stock 0.03M 0.03M 0.01M - 0.48M
Capital stock 0.03M 0.03M 0.01M 0.91M 0.48M
Retained earnings -186.87M -130.95M -104.38M -66.74M -47.26M
Other assets - - 0.00M - 0.01M
Cash 5.88M 68.42M 1.26M 1.24M 8.98M
Total current liabilities 8.21M 4.34M 13.90M 12.12M 3.91M
Net debt -5.61M -67.96M 3.36M 0.60M -
Short term debt 0.19M 0.18M 4.44M - -
Short long term debt - - 4.37M 1.85M 1.97M
Short long term debt total 0.27M 0.46M 4.62M - -
Other stockholder equity 206.87M 199.07M 102.24M - -
Property plant equipment - - - - 0.23M
Total current assets 27.09M 70.83M 11.65M 8.94M 9.61M
Net tangible assets - - - - 5.86M
Short term investments 19.85M 0.00M -9.08M - -
Net receivables 0.01M 0.01M 0.16M - -
Inventory - - 0.13M - -
Accounts payable 2.03M 0.57M 0.96M 1.79M 0.90M
Non currrent assets other 0.05M 0.05M 0.01M 0.01M 0.01M
Non current assets total 1.22M 1.94M 0.29M 0.17M 0.24M
Capital lease obligations 0.27M 0.46M 0.24M 0.08M 0.16M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -19.85M -0.25M 6.60M 5.21M -0.09M
Change to liabilities - - - - 0.52M
Total cashflows from investing activities -19.50M -0.25M 6.60M - -0.09M
Net borrowings - 0.00M 4.71M - -
Total cash from financing activities 0.03M 83.56M 16.44M -0.21M 13.08M
Change to operating activities - - - - 0.13M
Net income -55.92M -26.57M -37.64M -19.48M -8.52M
Change in cash -62.53M 58.08M 9.09M -7.74M 6.51M
Begin period cash flow 68.42M 10.34M 1.25M 8.99M 2.47M
End period cash flow 5.88M 68.42M 10.34M 1.25M 8.99M
Total cash from operating activities -43.06M -25.24M -13.95M -12.74M -6.47M
Issuance of capital stock 0.00M 83.56M 11.73M 0.00M 6.06M
Depreciation 0.72M 0.30M 0.12M 0.11M 0.03M
Other cashflows from investing activities - 1.36M 6.61M - -
Other cashflows from financing activities - 0.01M -0.01M - -0.94M
Change to netincome - - - - 0.77M
Capital expenditures 0.01M 1.60M 0.01M 0.03M 0.09M
Change in working capital 4.73M -2.63M -0.47M -0.76M 0.65M
Stock based compensation 7.77M 8.32M 0.99M 0.63M 0.87M
Other non cash items -0.36M -4.66M 23.05M 6.82M 0.59M
Free cash flow -43.07M -26.84M -13.96M -12.77M -6.57M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SKYE
Skye Bioscience, Inc. Common Stock		 0.08
9.54%		 0.92 - - 117.90 1.96 220.74 -2.56
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Skye Bioscience, Inc. Common Stock

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.

11250 El Camino Real, San Diego, CA, United States, 92130

858 410 0266

https://skyebioscience.com

2

Name Title Year Born
Mr. Punit S. Dhillon B.A., BA Exec. Chairman, Pres, CEO & Sec. 1980
Ms. Kaitlyn Melanie Arsenault CPA Chief Financial Officer 1987
Dr. Christopher G. Twitty Ph.D. Chief Scientific Officer 1972
Mr. Tu Diep M.Sc. Chief Devel. Officer NA
Mr. Punit S. Dhillon B.A. President, CEO & Director 1980
Mr. John P. Sharp CPA CFO and Principal Financial & Accounting Officer 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…